fig2

Electrochemical biosensing across microsampled blood and interstitial fluid for metabolic, hormonal, and therapeutic monitoring

Figure 2. Biological metabolic pathways and sensing strategy selection. (A and B) Metabolic processes in the human body; (A) Schematic illustration of major target organs associated with key biomarkers: (1) liver, (2) muscle, and (3) kidney; (B) Metabolic flow map of glucose, creatine, and lactate. These pathways illustrate the dynamic interactions between organ-specific metabolism and systemic physiological environments; (C) Relationship between biomarker molecular mass, PK dynamics, physiological turnover, and the resulting need for continuous monitoring; (D) Decision-making framework for selecting optimal sensing strategies based on the physicochemical and physiological profiles of target biomarkers. PK: Pharmacokinetic; NAD+: nicotinamide adenine dinucleotide (oxidized form); NADH: nicotinamide adenine dinucleotide (reduced form); LDH: lactate dehydrogenase; SAH: S-adenosyl-L-homocysteine; SAM: S-adenosyl-L-methionine; GAA: guanidinoacetate; GAMT: guanidinoacetate N-methyltransferase; AGAT: arginine: glycine amidino transferase.

Soft Science
ISSN 2769-5441 (Online)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/